New Gyros kit supports cell and gene therapy

pharmafile | October 1, 2021 | News story | Medical Communications  

Gyros Protein Technologies, leading provider of peptide synthesisers and reagents, has introduced the Gyrolab® AAV9 Titer Kit to support AAV-based cell and gene therapy production. This new kit will enable researchers to generate more data in less time, to support viral vector bioprocess analytics, to determine the physical titer in adeno-associated virus serotype 9 (AAV9) vector-based cell and gene therapy manufacturing.

The Gyrolab kit is the newest addition to the company’s existing range of ready-to-use kits, increasing their offering for analytical characterisation during manufacturing and purification of cell and gene therapies. This also complements the recently launched kits, such as the HEK 293 HCP Solution for Gyrolab.

The AAV9 serotype has a high ability to cross the blood-brain barrier and target the central nervous system with high efficiency. This makes it attractive as a gene delivery vector. The kit also supports improved development time and streamlined process transfer, due to the standardised reagents and validated methods of the Gyrolab platform.

The AAV9 Titer Kit provides fast results, enabling 96 data points to be generated in 80 minutes, and holds the ability to handle small sample volumes, helping to reduce development timelines of novel biotherapeutics, including cell and gene therapies.

Mark Vossenaar, Vice President, General Manager, Gyros Protein Technologies, commented: “The addition of Gyrolab AAV9 Titer Kit to our portfolio of ready-to-use kits exemplifies our commitment to offering the whole range of tools required for analytical characterisation during manufacturing and purification of cell and gene therapies.

“Physical titer determination is one of the key quality attributes of the FDA process validation guidelines and our new kit will enable researchers to maximise performance and productivity when developing therapies based on the AAV9 serotype, which will ultimately reduce the time needed to produce patient treatments.”

The Analytical Science team at Pharmaron Gene Therapy added: “We beta-tested the Gyrolab AAV9 Titer Kit and found excellent linearity and comparability with our commercial ELISA across a range of typical in-process samples. The broad dynamic range and small volume requirements will make it a valuable asset within our bioanalytical toolbox.”

Lina Adams

Related Content

No items found

Latest content